Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

In a phase 1 trial, Sebetralstat was shown to be able to suppress plasma kallikrein activity nearly completely. A single 600 mg dose of Sebetralstat produced a 98% inhibition of plasma kallikrein ...

One capsule of Orladeyo per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to ...